增加周期性氨酸单酸响应元素与耐药性的发病密切相关
Jing-Xuan Li1, Dai Shi2, Si-Ying Ren1,3
1Clinical College of Guizhou, Medical University, Guiyang, Guizhou, 561113, China.
Current neurovascular research
|March 12, 2024
概括
增强的cAMP反应元素结合蛋白 (CREB) 表达通过负调节GABA-A受体促进耐药性 (DRE). 抑制CREB可能会降低DRE发生率,提供潜在的治疗标.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
背景情况:
- 耐药性 (DRE) 是一种具有挑战性的神经疾病.
- γ-氨基黄油酸-a (GABAA) 受体与的耐药性有关.
- cAMP反应元素结合蛋白 (CREB) 是GABAA转录的关键调节者.
研究的目的:
- 调查CREB在DRE发展中的作用.
- 检查CREB对DRE中GABA相关受体的影响.
主要方法:
- 在大鼠海马中,通过lentiviral transfection操纵CREB表达.
- 建立了一个-皮洛卡尔诱导的模型.
- 使用西部涂抹和qPCR量化GABAA受体亚单元表达 (α1,β2,γ2) 和CREB水平.
主要成果:
- 增加CREB表达加剧了发作的频率和持续时间.
- 减少CREB表达减少了发作的严重程度,频率和持续时间.
- 发现CREB水平会负面调节GABAA受体表达和转录水平.
结论:
- 增强的CREB表达促进了DRE.
- 在CREB中,GABAA受体表达被负面调节.
- 抑制CREB可能为DR.RE提供治疗策略.
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
345
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
345
Antiepileptic Drugs: GABAergic Pathway Potentiators
399
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
399
Arteries of the Lower Limbs
189
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
189
Antiepileptic Drugs: Potassium Channel Activators
183
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
183
Desensitization and Tachyphylaxis
1.7K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.7K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
296
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
296


